Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer
Interventions: DRUG: eribulin|DRUG: carboplatin|DRUG: trastuzumab
Sponsor: Vector Oncology
Collaborators: Eisai Inc.